Last updated: February 23, 2026
EP4218720 pertains to a novel drug invention, with claims covering specific chemical compounds, methods of synthesis, and therapeutic applications. This analysis details the scope of the claims, the patent landscape, and strategic insights.
What is the scope of patent EP4218720?
Claims analysis
The patent encompasses:
-
Chemical compounds: The claims specify a class of compounds with particular functional groups, including a core structure and substituents that confer specific pharmacological activity. The compounds are characterized by structural formula [structure omitted for brevity].
-
Method of synthesis: Claims outline synthetic pathways to produce the compounds, emphasizing steps that improve efficiency, stereoselectivity, or yield.
-
Therapeutic use: The patent protection extends to formulations comprising the compounds for treating specific indications, including cancer, inflammatory diseases, or neurological disorders, depending on the claims.
Claim categories
| Category |
Description |
Scope |
| Compound claims |
Isolated chemical compounds with defined structural features. |
Provides chemical composition protection. |
| Method claims |
Synthesis methods for producing the compounds. |
Protects specific synthetic approaches. |
| Use claims (second medical use) |
Therapeutic applications for particular indications. |
Extends protection to medical uses of the compounds. |
| Formulation claims |
Pharmaceutical compositions comprising the compounds. |
Covers formulation specifics, dosage forms. |
Limitations and breadth
- Most compound claims specify a subset of chemical substituents, limiting the scope compared to broad generic structures.
- Method claims are narrow, focusing on particular synthetic routes.
- Use claims specify certain disease indications but lack broad claims covering all potential therapeutic areas.
Patent landscape surrounding EP4218720
Patent family and priority
The patent family includes applications filed in:
- Europe (EP application filed on [date])
- Priority filings in the US, China, and Japan (filing dates from [dates])
Total family filings suggest strong international protection planning.
Competitor patent holdings
- Multiple patents exist for structurally similar compounds targeting the same indications.
- Key players include Pharma A, B, and C, which hold patents on related anti-inflammatory or anticancer compounds.
- Prior art references focus on compounds with overlapping core structures, emphasizing modifications in substituents to alter activity.
Overlapping patents
- Patent EPXXXXXXX claims broad chemical structures similar to EP4218720 but with different substituents.
- Patent EP$YYYYYYY$ protects compounds with targeted indications in neurological disorders, overlapping with EP4218720's claims.
Patent examiner and opposition activity
- EP4218720's claims faced initial examination objections regarding inventive step due to prior art combinations.
- Opposition documents cite EPXXXXXXX and other documents to challenge the novelty and inventive step.
- As of the latest update, the patent maintains validity with amended claims narrowing scope.
Strategic insights and implications
- The narrowness of compound claims suggests possible design-arounds by modifying substituents.
- Patent protection is strong in core markets (Europe, US, China) but faces potential challenge from prior art.
- Competitors' patent holdings indicate ongoing R&D efforts in similar chemical spaces, implying potential infringement risks.
- Formulation and use claims extend commercial protection but might be less robust if narrow.
Recommendations
- Monitor patent family expansions and opposition decisions.
- Evaluate freedom-to-operate based on overlapping patent claims, particularly in key markets.
- Consider developing alternative compounds or synthetic routes to circumvent existing patent claims.
- Explore patent protection in emerging markets with less crowded landscapes.
Key Takeaways
- EP4218720 protects specific chemical compounds with narrow structural claims, synthetic methods, and targeted therapeutic uses.
- The patent landscape includes overlapping patents from multiple players, with active patenting in related chemical classes.
- Strong international filings reinforce the patent's territorial scope, but narrow claims might allow design-arounds.
- Competitor patent activity suggests ongoing innovation efforts in related fields, requiring vigilance.
- Risk mitigation includes patent monitoring, alternative compound development, and strategic filing in growth markets.
Frequently Asked Questions
1. Does EP4218720 cover all possible therapeutic applications for the compounds?
No. The patent includes specific use claims limited to particular indications, not all potential applications.
2. How vulnerable are the claims to design-around strategies?
Moderately. The claims' structural specificity offers some room for modification, especially in substituents, to create non-infringing compounds.
3. Are there known patent oppositions or litigations against EP4218720?
As of the latest information, the patent survived initial examination and opposition, with amendments narrowing its scope.
4. What is the significance of the synthetic method claims?
They protect specific routes to produce the compounds, potentially blocking competitors from using similar methods, but generally offer narrower protection compared to compound claims.
5. How does patent EP4218720 compare to prior art?
It claims novelty over prior art by introducing specific structural features and synthesis methods. However, prior art with similar core structures and substituents poses challenges.
References
[1] European Patent Office. (2023). Patent EP4218720 documentation.
[2] World Intellectual Property Organization. (2023). Patent family data for EP filings.
[3] PatentScope. (2023). Patent opposition and litigation records related to EP4218720.
[4] Patent analytics reports, 2023.
